2018 American Transplant Congress
The First Series of Ischemia-Free Liver Transplantation in Human
BACKGROUND&AIMS: Ischemia and reperfusion injury (IRI) is known as an inevitable event leading to early and late graft failure. We have performed the first case…2018 American Transplant Congress
Efficacy and Safety of Immediate- and Prolonged-Release Tacrolimus in De Novo Pediatric Transplantation: Randomized Study
This study assessed long-term efficacy/safety of prolonged-release tacrolimus (PR-T) vs immediate-release tacrolimus (IR-T) in de novo pediatric transplant pts. Phase II, parallel-group, multicenter, open-label study…2018 American Transplant Congress
Reducing No-Show Rate and Filling Cancelled Appointments: Multi-Faceted Interventions Markedly Reduced Time to Kidney Transplant Evaluation
Piedmont Transplant Institute, Piedmont Atlanta Hospital, Atlanta, GA.
Introduction: Time from referral to appointment for kidney transplant evaluation is an important metric. Demands of dialysis schedules and transportation logistics typically lead to high…2018 American Transplant Congress
Procurement Travel Safety: Current Practices, Accident Frequency, Perceptions of Safety and Means to Reduce Risk
Emory Transplant Center, Emory University, Atlanta, GA.
Transplant procurement teams travel extensively. Though considered hazardous, little data on the necessity and risks of this travel exist. We conducted a survey of ASTS…2018 American Transplant Congress
Medication Reconciliation in Abdominal Transplantation
Medication adherence post transplantation is vital. Upon discharge, abdominal transplant patients receive a medication list from the electronic medical record (EMR) and obtain a medication…2018 American Transplant Congress
12-Months Evolution of Anti-HLA Antibodies Donor Specific Antibodies after Rescue Switch from CNi-Based Immunosuppressive Regimen to Belatacept in Kidney Allograft Recipients
IntroductionAfter kidney transplantation, long-term immunosuppression with calcineurin inhibitors (CNIs) or mTOR inhibitors (mTORi) leads to adverse effects, such as nephrotoxicity and proteinuria. Currently, available data…2018 American Transplant Congress
Everolimus with Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplant Recipients: Efficacy and Safety Outcomes from the TRANSFORM Study
1TRANSFORM Study Group, Livingston; 2Novartis Pharma AG, Basel, Switzerland.
Purpose: Everolimus (EVR)-facilitated calcineurin inhibitor (CNI) reduction regimens help prevent long-term CNI nephrotoxicity in kidney transplant recipients (KTxRs). TRANSFORM (NCT01950819) is the largest study in…2018 American Transplant Congress
Living Donor Nephrectomy: Is It as Safe as It Can Be? Analysis of Living Donor Deaths in the United States
The reported rate of death from living donor nephrectomy is 3 in 10,000 donations. Although this risk is low, the important question is how many…2018 American Transplant Congress
Evaluation of Allergy to Tacrolimus in Kidney Transplant Candidates and Recipients with a History of Macrolide Antibiotic Allergy
Background: Tacrolimus (TAC) is considered a drug of choice for maintenance immunosuppression among kidney transplant (KTX) recipients. Because of structural resemblances between macrolide antibiotics (azithromycin,…2018 American Transplant Congress
Opioid Use Following Ultrasound-Guided Transverse Abdominis Plane Blocks in Living Donor Nephrectomy Patients
Purpose: Post-operative pain management is of major concern in living donor nephrectomy patients. Opioids are often used for post-surgical pain, however they are associated with…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 19
- Next Page »